| Title |
Critical appraisal of eculizumab for atypical hemolytic uremic syndrome
|
|---|---|
| Published in |
Journal of Blood Medicine, April 2016
|
| DOI | 10.2147/jbm.s36249 |
| Pubmed ID | |
| Authors |
Lilian M Pereira Palma, Craig B Langman |
| Abstract |
The biology of atypical hemolytic uremic syndrome has been shown to involve inability to limit activation of the alternative complement pathway, with subsequent damage to systemic endothelial beds and the vasculature, resulting in the prototypic findings of a thrombotic microangiopathy. Central to this process is the formation of the terminal membrane attack complex C5b-9. Recently, application of a monoclonal antibody that specifically binds to C5, eculizumab, became available to treat patients with atypical hemolytic uremic syndrome, replacing plasma exchange or infusion as primary therapy. This review focuses on the evidence, based on published clinical trials, case series, and case reports, on the efficacy and safety of this approach. |
X Demographics
The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 13% |
| Canada | 2 | 13% |
| Australia | 1 | 7% |
| Egypt | 1 | 7% |
| United Kingdom | 1 | 7% |
| Unknown | 8 | 53% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 12 | 80% |
| Practitioners (doctors, other healthcare professionals) | 2 | 13% |
| Scientists | 1 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 68 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Malaysia | 1 | 1% |
| Brazil | 1 | 1% |
| Unknown | 66 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 10 | 15% |
| Researcher | 10 | 15% |
| Student > Postgraduate | 6 | 9% |
| Student > Master | 6 | 9% |
| Student > Bachelor | 5 | 7% |
| Other | 17 | 25% |
| Unknown | 14 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 49% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 9% |
| Nursing and Health Professions | 4 | 6% |
| Agricultural and Biological Sciences | 2 | 3% |
| Immunology and Microbiology | 2 | 3% |
| Other | 5 | 7% |
| Unknown | 16 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 September 2019.
All research outputs
#2,642,184
of 25,000,733 outputs
Outputs from Journal of Blood Medicine
#26
of 323 outputs
Outputs of similar age
#41,549
of 306,147 outputs
Outputs of similar age from Journal of Blood Medicine
#3
of 8 outputs
Altmetric has tracked 25,000,733 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.9. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 306,147 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.